|
1
|
Wolin EM: Advances in the diagnosis and
management of well-differentiated and intermediate-differentiated
neuroendocrine tumors of the lung. Chest. 151:1141–1146.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Oberndorfer S: Karzinoide tumoren des
dünndarms. Frankfurter Zeischrift Pathol. 1:425–432. 1907.
|
|
3
|
Pelosi G, Bianchi F, Hofman P, Pattini L,
Ströbel P, Calabrese F, Naheed S, Holden C, Cave J, Bohnenberger H,
et al: Recent advances in the molecular landscape of lung
neuroendocrine tumors. Expert Rev Mol Diagn. 19:281–297.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Azzopardi JG: Oat-cell carcinoma of the
bronchus. J Pathol Bacteriol. 78:513–519. 1959.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gould VE: Neuroendocrinomas and
neuroendocrine carcinomas: APUD cell system neoplasms and their
aberrant secretory activities. Pathol Annu. 12:33–62.
1977.PubMed/NCBI
|
|
6
|
Arrigoni MG, Woolner LB and Bernatz PE:
Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg.
64:413–421. 1972.PubMed/NCBI
|
|
7
|
Eloesser L: Transthoracic bronchotomy for
removal of benign tumors of the bronchi. Ann Surg. 112:1067–1070.
1940.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Melosky B: Low grade neuroendocrine tumors
of the lung. Front Oncol. 7(119)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Benzerdjeb N, Berna P and Sevestre H:
GLUT1: A novel tool reflecting proliferative activity of lung
neuroendocrine tumors? Pathol Int. 67:32–36. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Peinado P, Arco CDD and Fernández-Aceñero
MJ: Neuroendocrine tumors in rare locations: Description of 27
cases. Med Clin (Barc). 155:460–461. 2020.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
12
|
Warren WH, Gould VE, Faber LP, Kittle CF
and Memoli VA: Neuroendocrine neoplasms of the bronchopulmonary
tract. A classification of the spectrum of carcinoid to small cell
carcinoma and intervening variants. J Thorac Cardiovasc Surg.
89:819–825. 1985.PubMed/NCBI
|
|
13
|
Lázaro S, Pérez-Crespo M, Lorz C,
Bernardini A, Oteo M, Enguita AB, Romero E, Hernández P, Tomás L,
Morcillo MÁ, et al: Differential development of large-cell
neuroendocrine or small-cell lung carcinoma upon inactivation of 4
tumor suppressor genes. Proc Natl Acad Sci USA. 116:22300–22306.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hauso O, Gustafsson BI, Kidd M, Waldum HL,
Drozdov I, Chan AK and Modlin IM: Neuroendocrine tumor
epidemiology: Contrasting Norway and North America. Cancer.
113:2655–2664. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Modlin IM, Lye KD and Kidd M: A 5 decade
analysis of 13,715 carcinoid tumors. Cancer. 97:934–959.
2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Broder MS, Cai B, Chang E and Neary MP:
Incidence and prevalence of neuroendocrine tumors of the lung:
Analysis of a US commercial insurance claims database. BMC Pulm
Med. 18(135)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rekhtman N: Neuroendocrine tumors of the
lung: An update. Arch Pathol Lab Med. 134:1628–1638.
2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Travis WD: Advances in neuroendocrine lung
tumors. Ann Oncol. 21 (Suppl 7):vii65–vii71. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Caplin ME, Baudin E, Ferolla P, Filosso P,
Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, et
al: Pulmonary neuroendocrine (carcinoid) tumors: European
neuroendocrine tumor society expert consensus and recommendations
for best practice for typical and atypical pulmonary carcinoids.
Ann Oncol. 26:1604–1620. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Travis WD, Brambilla E, Muller-Hermelink
HK and Harris CC (eds): World Health Organization classification of
tumours. Pathology and genetics of tumours of the lung, pleura,
thymus and heart. IARC Press, Lyon, pp179-184, 2004.
|
|
21
|
Rindi G, Klimstra DS, Abedi-Ardekani B,
Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M,
El-Naggar AK, et al: A common classification framework for
neuroendocrine neoplasms: An international agency for research on
cancer (IARC) and World Health Organization (WHO) expert consensus
proposal. Mod Pathol. 31:1770–1786. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Simbolo M, Mafficini A, Sikora KO, Fassan
M, Barbi S, Corbo V, Mastracci L, Rusev B, Grillo F, Vicentini C,
et al: Lung neuroendocrine tumours: Deep sequencing of the four
World Health Organization histotypes reveals chromatin-remodelling
genes as major players and a prognostic role for TERT, RB1, MEN1
and KMT2D. J Pathol. 241:488–500. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hendifar AE, Marchevsky AM and Tuli R:
Neuroendocrine tumors of the lung: Current challenges and advances
in the diagnosis and management of well-differentiated disease. J
Thorac Oncol. 12:425–436. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pelosi G, Bianchi F, Dama E, Simbolo M,
Mafficini A, Sonzogni A, Pilotto S, Harari S, Papotti M, Volante M,
et al: Most high-grade neuroendocrine tumours of the lung are
likely to secondarily develop from pre-existing carcinoids:
Innovative findings skipping the current pathogenesis paradigm.
Virchows Arch. 472:567–577. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Miller RR and Müller NL: Neuroendocrine
cell hyperplasia and obliterative bronchiolitis in patients with
peripheral carcinoid tumors. Am J Surg Pathol. 19:653–658.
1995.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Swarts DR, Ramaekers FC and Speel EJM:
Molecular and cellular biology of neuroendocrine lung tumors:
Evidence for separate biological entities. Biochim Biophys Acta.
1826:255–271. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Phan AT, Öberg K, Choi J, Harrison LH Jr,
Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA and
Maples WJ: North American Neuroendocrine Tumor Society (NANETS).
NANETS consensus guideline for the diagnosis and management of
neuroendocrine tumors: Well-differentiated neuroendocrine tumors of
the thorax (includes lung and thymus). Pancreas. 39:784–798.
2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Gould VE, Memoli VA and Dardi LE:
Multidirectional differentiation in human epithelial cancers. J
Submicrosc Cytol. 13:97–115. 1981.
|
|
29
|
Savu C, Melinte A, Lukadi JL, Mirvald C,
Savu C, Belu E, Diaconu C, Iliescu L, Balescu I, Stiru O, et al:
Neuroendocrine syndrome in bronchial carcinoid tumors. Exp Ther
Med. 20(200)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Detterbeck FC: Clinical presentation and
evaluation of neuroendocrine tumors of the lung. Thorac Surg Clin.
24:267–276. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zainal A, Akinsola O and Rajamani K:
Cushing syndrome secondary to primary neuroendocrine lung
carcinoma. Case Rep Endocrinol. 2019(1989260)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mitchell AN, Bakhos CT and Zimmerman EA:
Anti-Ri-associated paraneoplastic brainstem cerebellar syndrome
with coexisting limbic encephalitis in a patient with mixed large
cell neuroendocrine lung carcinoma. J Clin Neurosci. 22:421–423.
2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sobin LH, Gospodarowicz MK and Wittekind C
(eds): TNM classification of malignant tumours. 7th edition. John
Wiley & Sons, West Sussex, 2011.
|
|
34
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lohinai Z, Megyesfalvi Z, Suda K, Harko T,
Ren S, Moldvay J, Laszlo V, Rivard C, Dome B and Hirsch FR:
Comparative expression analysis in small cell lung carcinoma
reveals neuroendocrine pattern change in primary tumor versus lymph
node metastases. Transl Lung Cancer Res. 8:938–950. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Garg R, Bal A, Das A, Singh N and Singh H:
Proliferation marker (Ki67) in sub-categorization of neuroendocrine
tumours of the lung. Turk Patoloji Derg. 35:15–21. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Halimi M, Ghorbani T, Tabrizi AD, Khamnian
Z and Pourasghary S: Association of Ki67 antigen with mitotic
count, tumor size, and Necrosis in Neuroendocrine Tumors of Lung.
Cres J Med Biol Sci. 7:398–403. 2020.
|
|
38
|
Fabbri A, Cossa M, Sonzogni A, Papotti M,
Righi L, Gatti G, Maisonneuve P, Valeri B, Pastorino U and Pelosi
G: Ki-67 labeling index of neuroendocrine tumors of the lung has a
high level of correspondence between biopsy samples and surgical
specimens when strict counting guidelines are applied. Virchows
Arch. 470:153–164. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhao LH, Chen C, Mao CY, Xiao H, Fu P,
Xiao HL and Wang G: Value of SATB2, ISL1, and TTF1 to differentiate
rectal from other gastrointestinal and lung well-differentiated
neuroendocrine tumors. Pathol Res Pract. 215(152448)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Folpe AL, Gown AM, Lamps LW, Garcia R,
Dail DH, Zarbo RJ and Schmidt RA: Thyroid transcription factor-1:
Immunohistochemical evaluation in pulmonary neuroendocrine tumors.
Mod Pathol. 12:5–8. 1999.PubMed/NCBI
|
|
41
|
Del Gobbo A, Fusco N, Barella M, Ercoli G,
Sciarra A, Palleschi A, Pagni F, Marchiò C, Papotti M and Ferrero
S: CXCL12 expression is a bona fide predictor of recurrence in lung
neuroendocrine tumours; a multicentric study with emphasis on
atypical carcinoids-a short report. Cell Oncol (Dordr). 41:687–691.
2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kim M, Chung YS, Kim KA and Shim HS:
Genomic profiling and clinicopathological characteristics of
neuroendocrine tumors of the lung in East Asian patients. In Vivo.
34:3375–3385. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Gazzeri S, Gouyer V, Vour'ch C, Brambilla
C and Brambilla E: Mechanisms of p16INK4A inactivation in non
small-cell lung cancers. Oncogene. 16:497–504. 1998.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Malczewska A, Oberg K, Bodei L, Aslanian
H, Lewczuk A, Filosso PL, Wójcik-Giertuga M, Rydel M, Zielińska-Leś
I, Walter A, et al: NETest liquid biopsy is diagnostic of lung
neuroendocrine tumors and identifies progressive disease.
Neuroendocrinology. 108:219–231. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lázaro S, Pérez-Crespo M, Enguita AB,
Hernández P, Martínez-Palacio J, Oteo M, Sage J, Paramio JM and
Santos M: Ablating all three retinoblastoma family members in mouse
lung leads to neuroendocrine tumor formation. Oncotarget.
8:4373–4386. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Brominska B, Gabryel P,
Jarmołowska-Jurczyszyn D, Janicka-Jedyńska M, Trojanowski M,
Sawicka-Gutaj N, Czepczyński R, Gut P, Bromiński G, Dyszkiewicz W,
et al: Clinical significance of nestin and its association with
survival in neuroendocrine lung tumours. Pol J Pathol. 68:291–296.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Shimizu K, Goto Y, Kawabata-Iwakawa R,
Ohtaki Y, Nakazawa S, Yokobori T, Obayashi K, Kawatani N, Yajima T,
Kaira K, et al: Stathmin-1 is a useful diagnostic marker for
high-grade lung neuroendocrine tumors. Ann Thorac Surg.
108:235–243. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
George J, Walter V, Peifer M, Alexandrov
LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM,
et al: Integrative genomic profiling of large-cell neuroendocrine
carcinomas reveals distinct subtypes of high-grade neuroendocrine
lung tumors. Nat Commun. 9(1048)2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Tsuruoka K, Horinouchi H, Goto Y, Kanda S,
Fujiwara Y, Nokihara H, Yamamoto N, Keisuke A, Nakagawa K, Sakurai
H, et al: PD-L1 expression in neuroendocrine tumors of the lung.
Lung Cancer. 108:115–120. 2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Kim HS, Lee JH, Nam SJ, Ock CY, Moon JW,
Yoo CW, Lee GK and Han JY: Association of PD-L1 expression with
tumor-infiltrating immune cells and mutation burden in high-grade
neuroendocrine carcinoma of the lung. J Thorac Oncol. 13:636–648.
2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Inamura K, Yokouchi Y, Kobayashi M,
Ninomiya H, Sakakibara R, Nishio M, Okumura S and Ishikawa Y:
Relationship of tumor PD-L1 (CD274) expression with lower mortality
in lung high-grade neuroendocrine tumor. Cancer Med. 6:2347–2356.
2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ohtaki Y, Kaira K, Atsumi J, Nagashima T,
Kawashima O, Ibe T, Kamiyoshihara M, Onozato R, Fujita A, Yazawa T,
et al: Prognostic significance of PD-L1 expression and tumor
infiltrating lymphocytes in large cell neuroendocrine carcinoma of
lung. Am J Transl Res. 10:3243–3253. 2018.PubMed/NCBI
|
|
53
|
Zhang W, Girard L, Zhang YA, Haruki T,
Papari-Zareei M, Stastny V, Ghayee HK, Pacak K, Oliver TG, Minna JD
and Gazdar AF: Small cell lung cancer tumors and preclinical models
display heterogeneity of neuroendocrine phenotypes. Transl Lung
Cancer Res. 7:32–49. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Savu C, Grigorie V, Melinte A, Diaconu C,
Iliescu L, Dimitriu M, Balescu I and Bacalbasa N: Giant
intrathoracic schwannoma: A case report. In Vivo. 34:3527–3532.
2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Galvano A, Peri M, Guarini AA, Castiglia
M, Grassadonia A, De Tursi M, Irtelli L, Rizzo S, Bertani A,
Gristina V, et al: Analysis of systemic inflammatory biomarkers in
neuroendocrine carcinomas of the lung: Prognostic and predictive
significance of NLR, LDH, ALI, and LIPI score. Ther Adv Med Oncol.
12(1758835920942378)2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Sakakibara R, Kobayashi M, Takahashi N,
Inamura K, Ninomiya H, Wakejima R, Kitazono S, Yanagitani N,
Horiike A, Ichinose J, et al: Insulinoma-associated protein 1
(INSM1) is a better marker for the diagnosis and prognosis
estimation of small cell lung carcinoma than neuroendocrine
phenotype markers such as chromogranin A, synaptophysin, and CD56.
Am J Surg Pathol. 44:757–764. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Russo L, Grilli B, Minopoli A, Capozzi M,
Tafuto S, Correra M, Trillò G, Isgrò MA and Cavalcanti E: A
potential prognostic marker in primitive lung neuroendocrine tumor:
A case report. Int J Biol Markers. 35:102–106. 2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Leal JL, Peters G, Szaumkessel M, Leong T,
Asadi K, Rivalland G, Do H, Senko C, Mitcell PL, Quing CZ, et al:
NTRK and ALK rearrangements in malignant pleural mesothelioma,
pulmonary neuroendocrine tumours and non-small cell lung cancer.
Lung Cancer. 146:154–159. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Pirvu A, Angelescu D and Savu C: Localized
fibrous tumor of the pleura un unusual cause of severe
hypoglycaemia. Case report. Rev Med Chir Soc Med Nat Iasi.
120:628–630. 2016.PubMed/NCBI
|
|
60
|
Savu C, Melinte A, Posea R, Galie N,
Balescu I, Diaconu C, Cretoiu D, Dima S, Filipescu A, Balalau C and
Bacalbasa N: Pleural solitary fibrous tumors-a retrospective study
on 45 patients. Medicina (Kaunas). 56(185)2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Savu C, Melinte A, Balescu I and Bacalbasa
N: Azygos vein aneurysm mimicking a mediastinal mass. In Vivo.
34:2135–2140. 2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Sparaneo A, Fabrizio FP, la Torre A,
Graziano P, Di Maio M, Fontana A, Bisceglia M, Rossi A, Pizzolitto
S, De Maglio G, et al: Effects of KEAP1 silencing on the regulation
of NRF2 activity in neuroendocrine lung tumors. Int J Mol Sci.
20(2531)2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Brcic L, Kuchler C, Eidenhammer S, Pabst
D, Quehenberger F, Gazdar AF and Popper H: Comparison of four DLL3
antibodies performance in high grade neuroendocrine lung tumor
samples and cell cultures. Diagn Pathol. 14(47)2019.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Yoxtheimer LM, Heymann JJ, Cohen C, Rao
RA, Goyal A and Siddiqui MT: Immunohistochemical analysis of OTP
and NKX6.1 in neuroendocrine tumors of the lung and pancreas. Diagn
Cytopathol. 46:1010–1014. 2018.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Detassis S, Del Vescovo V, Grasso M,
Masella S, Cantaloni C, Cima L, Cavazza A, Graziano P, Rossi G,
Barbareschi M, et al: miR375-3p distinguishes low-grade
neuroendocrine from non-neuroendocrine lung tumors in FFPE samples.
Front Mol Biosci. 7(86)2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Jeung MY, Gasser B, Gangi A, Charneau D,
Ducroq X, Kessler R, Quoix E and Roy C: Bronchial carcinoid tumors
of the thorax: Spectrum of radiologic findings. Radiographics.
22:351–365. 2002.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Boutsikou E, Porpodis K, Chatzipavlidou V,
Hardavella G, Gerasimou G, Domvri K, Papadopoulos N, Avramidou V,
Spyratos D, Kontakiotis T and Zarogoulidis K: Predictive value of
99MTC-hynic-toc scintigraphy in lung neuroendocrine tumor
diagnosis. Technol Cancer Res Treat.
18(1533033819842586)2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Tripathy S, Ballal S, Yadav MP, Joshi P,
Bal C and Damle NA: Coexistence of multiple metastatic lesions
showing various grades of differentiation in a single patient with
neuroendocrine tumor of lung as primary: A combined modality
approach of 68Ga-DOTANOC positron emission
tomography/computed tomography and
18F-fluorodeoxyglucose positron emission
tomography/computed tomography imaging. Indian J Nucl Med.
34:260–262. 2019.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Singh S, Bergsland EK, Card CM, Hope TA,
Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, et
al: Commonwealth neuroendocrine tumour research collaboration and
the North American neuroendocrine tumor society guidelines for the
diagnosis and management of patients with lung neuroendocrine
tumors: An international collaborative endorsement and update of
the 2015 European neuroendocrine tumor society expert consensus
guidelines. J Thorac Oncol. 15:1577–1598. 2020.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Filosso PL, Guerrera F, Evangelista A,
Galassi C, Welter S, Rendina EA, Travis W, Lim E, Sarkaria I and
Thomas PA: ESTS Lung Neuroendocrine Working Group Contributors.
Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma:
Results from the European society for thoracic surgeons lung
neuroendocrine tumours retrospective database. Eur J Cardiothorac
Surg. 52:339–345. 2017.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Mauclet C, Duplaquet F, Pirard L, Rondelet
B, Dupont M, Pop-Stanciu C, Vander Borght T, Remmelink M, D'Haene
N, Lambin S, et al: Complete tumor response of a locally advanced
lung large-cell neuroendocrine carcinoma after palliative thoracic
radiotherapy and immunotherapy with nivolumab. Lung Cancer.
128:53–56. 2019.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Balasubramaniam S, Redon CE, Peer CJ,
Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner
WM, et al: Phase I trial of belinostat with cisplatin and etoposide
in advanced solid tumors, with a focus on neuroendocrine and small
cell cancers of the lung. Anticancer Drugs. 29:457–465.
2018.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Peri M and Fazio N: Clinical evaluation of
everolimus in the treatment of neuroendocrine tumors of the lung:
Patient selection and special considerations. A systematic and
critical review of the literature. Lung Cancer (Auckl). 11:41–52.
2020.PubMed/NCBI View Article : Google Scholar
|
